3Locatelli F, Pozzoni P, Tentori F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003,18 Suppl 7:2-9.
4Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol, 2002,13:745-753.
5Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol, 2003,41:47-55.
6Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int, 1995,47:186-192.
7Sarnak MJ, Levey AS, Schoolwerth AC,et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003,108:2154-2169.
8Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 Study. Kidney Int, 2003,63:1462-1467.
9Wong JS, Rort FK, Hulbert-Shearon TE, et al. Survival advantage in Asian American end-stage renal disease patients. Kidney Int, 1999,55:2515-2523.
10Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 1998,32:s112-s119.
3Chuang S Y,Chen J H,Yeh W T,et al.Hypenaricemia and increased risk of ischemic heart disease in a large Chinese cohort.Int J Cardiol,2012,154(3):316-321.
4Ratto E,Leoncini G,Viazzi F,et al.Glomerular filtration rate and cardiovasc~ar risk:Prognostic and therapeutic implications.G Ital Nefrol,2008,25(1):21-31.
5Tomiyama H,Koji Y,Yambe M,et al.Brachial ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome.Circ,2005,69:815-822.
6Raman P G,Thakur B S,Mathew V.Ankle brachial index as a predictor of generalized atherosclerosis.J Assoc Physicians India.2001,49:1074-1077.
8Yamada S,Yoshida H,Taniguchi M,et al. Effectiveness of lantha-num carbonate treatment used in combination with other phosphatebinders in peritoneal dialysis patients[J]. Intern Med,2012,51(16):2097-2104.
9Isakova T,Xie H,Yang W,et al. Fibroblast growth factor 23 andrisks of mortality and end - stage renal disease in patients withchronic kidney disease[J]. JAMA,2011,305(23):2432-2439.
